Early estimates show the 2023-24 updated monovalent XBB.1.5 COVID-19 vaccine offers significant protection against symptomatic infection, with effectiveness varying by age and time since vaccination.
Early estimates show the 2023-24 updated monovalent XBB.1.5 COVID-19 vaccine offers significant protection against symptomatic infection, with effectiveness varying by age and time since vaccination.